Diagnosis, Imaging, and Pathology
At a Glance
Most small, superficial lumps with classic ultrasound features can be evaluated without extensive testing, but a lipoma larger than 5 centimeters, deep, rapidly growing, or unusual may need specialist MRI and a planned biopsy; imaging alone cannot confirm the final diagnosis.
Determining whether a fatty lump is a standard lipoma or a more complex growth requires a structured diagnostic pathway. This process usually begins with a physical exam and moves toward advanced imaging and molecular testing if certain “red flags” are present [1].
A Simple Diagnostic Pathway
- Clinical Examination: To assess the size, depth, and feel of the lump.
- Ultrasound: Often the first step for a concordant superficial lesion.
- Specialist MRI / Referral: Often recommended for deep, enlarging, large, or indeterminate lesions.
- Planned Biopsy: Used when indicated by imaging.
- Pathology & Molecular Testing: Selected by a specialist pathologist according to the differential diagnosis.
The Initial Evaluation: Ultrasound
For small, soft lumps located just under the skin (superficial), an ultrasound is often the first step [2]. Ultrasound is an accessible, painless test excellent for determining if a lump is a solid mass or a fluid-filled cyst. A “classic” lipoma on an ultrasound appears as a smooth, oval-shaped mass that looks similar to the surrounding fat [3]. If the lump is smaller than 5 centimeters and has these classic features, your doctor may decide that no further imaging is needed [2].
Advanced Imaging: The Role of MRI
If a mass is larger than 5 centimeters, is located deep within a muscle, or is growing quickly, an MRI (Magnetic Resonance Imaging) is often recommended or may warrant specialist-directed assessment [1][4]. MRI provides a high-contrast map of the tissues, allowing doctors to look “inside” the fatty mass for features that a standard ultrasound might miss. An MRI scan requires you to lie still inside a scanner tube, usually for 30 to 60 minutes.
On an MRI, radiologists look for specific warning signs of an atypical lipomatous tumor (ALT) or well-differentiated liposarcoma (WDL) [5]:
- Septa Thickness: Most lipomas have very thin internal walls (septa). If these walls are thicker than 2 millimeters or look irregular, it increases the suspicion of a more complex tumor [6][7].
- Non-fatty Components: While a lipoma is almost entirely fat, an ALT/WDL may contain solid “nodules” of non-fatty tissue [7][8].
- Fat Suppression: Specialists use a technique called fat suppression to “black out” normal fat on the scan. If parts of the tumor remain bright, it is a warning feature for the radiologist to investigate further [9].
Patients should not try to interpret MRI descriptions themselves, as these features are warning signs, not absolute proof of cancer. Imaging cannot by itself establish the final diagnosis.
The Biopsy: Getting a Tissue Sample
If imaging shows concerning features, the next step is often a core-needle biopsy [10]. In this procedure, under local anesthesia, a doctor uses a hollow needle to remove small cylinders of tissue. It is highly recommended that this biopsy be planned by a specialist at a sarcoma center [11]. This is because the path the needle takes (the biopsy tract) must be carefully chosen so it can be completely removed if surgery is later required [10][4].
Optional Section: Molecular Pathology Testing
If your doctor suspects an atypical tumor based on size or depth, the pathologist may use specific molecular tests [12]. A straightforward superficial benign lipoma is appropriately reported without this testing, but for complex cases, it is highly useful.
- MDM2 Gene Amplification (FISH): Pathologists use a technique called Fluorescence In Situ Hybridization (FISH) to count the copies of the MDM2 gene. If the gene is “amplified” (meaning there are too many copies), the diagnosis is likely ALT/WDL [13][14]. If the MDM2 count is normal, it provides strong supportive evidence of a benign lipoma [15]. However, this test is selectively interpreted alongside morphology and location, not as a standalone result.
- HMGA2: This gene is often “rearranged” or overactive in conventional lipomas [16]. While finding HMGA2 changes can help confirm a lump is a benign lipoma, it is an ancillary test [17][18].
Understanding Your Pathology Report
When you receive your final pathology report, its contents will appropriately differ depending on the specimen (biopsy vs. excision) and clinical question. If you had a large, deep, or atypical lesion removed, you may want to ask your doctor to explain:
- Histologic Subtype: Identifies if it is a conventional lipoma, angiolipoma, spindle cell, etc. [19].
- Tumor Size & Depth: Confirms the exact dimensions and whether it was above or below the fascia [20].
- Atypia: Notes if any cells look “strange” or “atypical” under the microscope [15].
- Mitotic Rate: A measure of how fast the cells are dividing [21].
- MDM2 Status: The result of the FISH test, if ordered (Positive or Negative for amplification) [13].
- Surgical Margins: (For resections only) States if the “edges” of the removed tissue are clear of tumor cells [22].
Rather than treating a missing item as evidence of an incomplete diagnosis, ask your specialist whether advanced molecular testing was needed for your specific lump [11].
Common questions in this guide
How do doctors diagnose a lipoma?
When does a lipoma need an MRI?
Can an ultrasound confirm that a lump is a lipoma?
What does MDM2 testing show in a lipoma?
Why must a lipoma biopsy be planned by a specialist?
What should I look for in a lipoma pathology report?
One line in your results can change your plan.
A small superficial lump with classic ultrasound features may lead your doctor to decide no further imaging is needed. We check your results against the latest research to help you prepare for what’s next.
Related questions
Get notified when new evidence is published on lipoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (22)
- 1
Soft tissue sarcoma in France in 2015: Epidemiology, classification and organization of clinical care.
Honoré C, Méeus P, Stoeckle E, Bonvalot S
Journal of visceral surgery 2015; (152(4)):223-30.
PMID: 26088366 - 2
Soft tissue tumor imaging in adults: European Society of Musculoskeletal Radiology-Guidelines 2023-overview, and primary local imaging: how and where?
Noebauer-Huhmann IM, Vanhoenacker FM, Vilanova JC, et al.
European radiology 2024; (34(7)):4427-4437 doi:10.1007/s00330-023-10425-5.
PMID: 38062268 - 3
A bump: what to do next? Ultrasound imaging of superficial soft-tissue palpable lesions.
Catalano O, Varelli C, Sbordone C, et al.
Journal of ultrasound 2020; (23(3)):287-300 doi:10.1007/s40477-019-00415-z.
PMID: 31786796 - 4
Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk.
Smolle MA, Andreou D, Tunn PU, et al.
EFORT open reviews 2017; (2(10)):421-431 doi:10.1302/2058-5241.2.170005.
PMID: 29209518 - 5
Spectrum of Fat-containing Soft-Tissue Masses at MR Imaging: The Common, the Uncommon, the Characteristic, and the Sometimes Confusing.
Gupta P, Potti TA, Wuertzer SD, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2016; (36(3)):753-66 doi:10.1148/rg.2016150133.
PMID: 27163592 - 6
Differentiating atypical lipomatous tumors from lipomas with magnetic resonance imaging: a comparison with MDM2 gene amplification status.
Knebel C, Neumann J, Schwaiger BJ, et al.
BMC cancer 2019; (19(1)):309 doi:10.1186/s12885-019-5524-5.
PMID: 30943944 - 7
Differentiation of Atypical Lipomatous Tumors from Lipomas: Our Experience with Visual Analysis of Conventional Magnetic Resonance Imaging.
Moran LM, Li Cai CY, Ramirez A, Royuela A
Journal of imaging 2025; (11(2)) doi:10.3390/jimaging11020047.
PMID: 39997549 - 8
Use of radiologic imaging to differentiate lipoma from atypical lipomatous tumor/well-differentiated liposarcoma: Systematic review.
Muhib M, Abidi SLF, Ahmed U, et al.
SAGE open medicine 2024; (12()):20503121241293496 doi:10.1177/20503121241293496.
PMID: 39526094 - 9
Qualitative evaluation of MRI features of lipoma and atypical lipomatous tumor: results from a multicenter study.
Nardo L, Abdelhafez YG, Acquafredda F, et al.
Skeletal radiology 2020; (49(6)):1005-1014 doi:10.1007/s00256-020-03372-5.
PMID: 31965239 - 10
Soft Tissue Tumors in Adults: ESSR-Approved Guidelines for Diagnostic Imaging.
Noebauer-Huhmann IM, Weber MA, Lalam RK, et al.
Seminars in musculoskeletal radiology 2015; (19(5)):475-82 doi:10.1055/s-0035-1569251.
PMID: 26696086 - 11
UK guidelines for the management of soft tissue sarcomas.
Hayes AJ, Nixon IF, Strauss DC, et al.
British journal of cancer 2025; (132(1)):11-31 doi:10.1038/s41416-024-02674-y.
PMID: 38734790 - 12
The value of a new diagnostic strategy for adipocytic soft tissue tumors in adults: A retrospective study.
Lepage B, Ropars M, Crepin V, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2023; (49(10)):107012 doi:10.1016/j.ejso.2023.107012.
PMID: 37572589 - 13
MDM2 and CDK4 Immunohistochemistry: Should It Be Used in Problematic Differentiated Lipomatous Tumors?: A New Perspective.
Clay MR, Martinez AP, Weiss SW, Edgar MA
The American journal of surgical pathology 2016; (40(12)):1647-1652 doi:10.1097/PAS.0000000000000713.
PMID: 27508976 - 14
Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center.
Thway K, Wang J, Swansbury J, et al.
Sarcoma 2015; (2015()):812089 doi:10.1155/2015/812089.
PMID: 25810689 - 15
Criteria for MDM2 fluorescence in situ hybridization testing in the diagnosis of well-differentiated adipocytic neoplasms: a retrospective utilization review of 1151 cases.
Flaman AN, Zhang L, Dickson BC, Demicco EG
Virchows Archiv : an international journal of pathology 2025; (487(6)):1279-1289 doi:10.1007/s00428-025-04342-9.
PMID: 41269286 - 16
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.
Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2015; (28(11)):1404-14 doi:10.1038/modpathol.2015.96.
PMID: 26336885 - 17
Clinical Application of Chromosome Microarray Analysis in the Diagnosis of Lipomatous Tumors.
Pei J, Flieder DB, Talarchek JN, et al.
Applied immunohistochemistry & molecular morphology : AIMM 2021; (29(8)):592-598 doi:10.1097/PAI.0000000000000923.
PMID: 33734108 - 18
Osteolipomas revisited: a detailed clinical, histologic and molecular characterisation.
Rammal R, Neyaz A, Hegazy S, et al.
Histopathology 2025; (87(4)):557-564 doi:10.1111/his.15514.
PMID: 40654063 - 19
Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma of the Salivary Gland and Its Diagnostic Challenges: A Case Report and Literature Review.
Khan B, Khan J, Al Hmada Y, Abbas S
International journal of surgical pathology 2026; 10668969261458405 doi:10.1177/10668969261458405.
PMID: 42484517 - 20
Atypical Pleomorphic Lipomatous Tumor: Expanding Our Current Understanding in a Clinicopathologic Analysis of 64 Cases.
Anderson WJ, Fletcher CDM, Jo VY
The American journal of surgical pathology 2021; (45(9)):1282-1292 doi:10.1097/PAS.0000000000001706.
PMID: 33782225 - 21
Deep Introspection Regarding Cumulative Prognostic Factors in Liposarcoma and Atypical Lipomatous Tumor.
Ciongariu AM, Radu ȘȘ, Dumitru AV, et al.
Medicina (Kaunas, Lithuania) 2025; (61(8)) doi:10.3390/medicina61081431.
PMID: 40870476 - 22
Atypical Spindle Cell Lipomatous Tumor: Clinicopathologic Characterization of 232 Cases Demonstrating a Morphologic Spectrum.
Mariño-Enriquez A, Nascimento AF, Ligon AH, et al.
The American journal of surgical pathology 2017; (41(2)):234-244 doi:10.1097/PAS.0000000000000770.
PMID: 27879515
This page explains lipoma imaging, biopsy, and pathology for education; it cannot diagnose your lump or replace medical advice. Ask your clinician or a sarcoma specialist to interpret your results.